<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain><z:hpo ids='HP_0002140'>Ischemic stroke</z:hpo> is a significant health problem affecting over 6 million people in the United States alone </plain></SENT>
<SENT sid="1" pm="."><plain>In addition to surgical and thrombolytic therapeutic strategies for <z:hpo ids='HP_0001297'>stroke</z:hpo>, neuroprotective therapies may offer additional benefit </plain></SENT>
<SENT sid="2" pm="."><plain><z:chebi fb="0" ids="52640">N-acylethanolamines</z:chebi> (NAEs) are signaling <z:chebi fb="23" ids="18059">lipids</z:chebi> whose synthesis is upregulated in response to <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischemia</z:e>, suggesting that they may be neuroprotective </plain></SENT>
<SENT sid="3" pm="."><plain>To date only three NAEs, <z:chebi fb="0" ids="2700">arachidonylethanolamide</z:chebi> (NAE 20:4), palmitoylethanolamide (NAE 16:0) and oleoylethanolamide (NAE 18:1) have shown to exert neuroprotective effect in animal models for <z:hpo ids='HP_0001297'>stroke</z:hpo> </plain></SENT>
<SENT sid="4" pm="."><plain>Here, we describe neuroprotective effects of the hitherto uncharacterized NAEs, lauroylethanolamide (NAE 12:0) and linoleoylethanolamide (NAE 18:2) in a middle cerebral <z:mp ids='MP_0006134'>artery occlusion</z:mp> model of <z:hpo ids='HP_0001297'>stroke</z:hpo> </plain></SENT>
<SENT sid="5" pm="."><plain>Pretreatment with NAE 18:2 prior to <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischemia</z:e>/reperfusion (I/R) injury resulted in both significantly reduced cortical <z:mpath ids='MPATH_124'>infarct</z:mpath> volume and improved functional outcome as determined using the neurological deficit score </plain></SENT>
<SENT sid="6" pm="."><plain>NAE 12:0 improved neurological deficits without a significant reduction lesion size </plain></SENT>
<SENT sid="7" pm="."><plain>Our results suggest that NAEs, as a whole, provide neuroprotection during I/R injury and may have therapeutic benefit when used as complementary treatment with other therapies to improve <z:hpo ids='HP_0001297'>stroke</z:hpo> outcome </plain></SENT>
</text></document>